GABA B -mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Gandal, M J ^a   Sisti, J ^a   Klook, K ^a,b   Ortinski, P I ^a   Leitman, V ^a   Liang, Y ^a   Thieu, T ^a   Anderson, R ^a   Pierce, R C ^a   Jonak, G ^a   Gur, R E ^c   Carlson, G ^a   Siegel, S J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

animal model; GABAergic signaling; gamma oscillation; neuropsychiatric disease; NMDA receptor

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; BACLOFEN; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PARVALBUMIN; RISPERIDONE; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; FLUOROBENZENE; L 838,417; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRIAZOLE DERIVATIVE;

ACOUSTIC REFLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORTICAL SYNCHRONIZATION; EVOKED AUDITORY RESPONSE; EXCITATORY INHIBITORY BALANCE; EXCITATORY POSTSYNAPTIC POTENTIAL; GAMMA RHYTHM; INHIBITORY POSTSYNAPTIC POTENTIAL; INTERNEURON; LOCOMOTION; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NERVE CELL EXCITABILITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PYRAMIDAL NERVE CELL; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; SPATIAL MEMORY; STARTLE REFLEX; WORKING MEMORY; ANIMAL; AUTISM; DISEASE MODEL; DRUG EFFECT; EXPLORATORY BEHAVIOR; GENETICS; IN SITU HYBRIDIZATION; INTELLECTUAL IMPAIRMENT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCHIZOPHRENIA; SYNAPTIC POTENTIAL; TRANSGENIC MOUSE;

ANIMALS; AUTISTIC DISORDER; BACLOFEN; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS, AUDITORY; EXPLORATORY BEHAVIOR; FLUOROBENZENES; GABA-B RECEPTOR AGONISTS; IN SITU HYBRIDIZATION; INTELLECTUAL DISABILITY; INTERNEURONS; MALE; MICE; MICE, TRANSGENIC; PARVALBUMINS; PHENOTYPE; PYRAMIDAL CELLS; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SYNAPTIC POTENTIALS; TRIAZOLES;

EID: 84866106557     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.69     Document Type: Article

References (81)

1. Begni S, Moraschi S, Bignotti S, Fumagalli F, Rillosi L, Perez J et al. Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol Psychiatry 2003; 53: 617-619. (Pubitemid 36385063)
2. Galehdari H, Pooryasin A, Foroughmand A, Daneshmand S, Saadat M. Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population. J Mol Neurosci 2009; 38: 178-181.
3. Zhao X, Li H, Shi Y, Tang R, Chen W, Liu J et al. Significant association between the genetic variations in the 50 end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 2006; 59: 747-753.
4. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2011; 168: 930-946.
5. Iwayama-Shigeno Y, Yamada K, Itokawa M, Toyota T, Meerabux JM, Minabe Y et al. Extended analyses support the association of a functional (GT)n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci Lett 2005; 378: 102-105. (Pubitemid 40354295)
6. Li D, He L. Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis. Genet Med 2007; 9: 4-8. (Pubitemid 46105843)
7. Barnby G, Abbott A, Sykes N, Morris A, Weeks DE, Mott R et al. Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J Hum Genet 2005; 76: 950-966. (Pubitemid 40705432)
8. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011; 43: 585-589.
9. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011; 474: 380-384.
10. Gai X, Xie HM, Perin JC, Takahashi N, Murphy K, Wenocur AS et al. Rare structural variation of synapse and neurotransmission genes in autism. Mol Psychiatry 2012; 17: 402-411.
11. Bangash MA, Park JM, Melnikova T, Wang D, Jeon SK, Lee D et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 2011; 145: 758-772.
12. Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C et al. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci 2010; 30: 2115-2129.
13. Yun SH, Trommer BL. Fragile X mice: reduced long-term potentiation and N-Methyl-DAspartate receptor-mediated neurotransmission in dentate gyrus. J Neurosci Res 2011; 89: 176-182.
14. Maliszewska-Cyna E, Bawa D, Eubanks JH. Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain. Neuroscience 2010; 168: 624-632.
15. Hayashi-Takagi A, Takaki M, Graziane N, Seshadri S, Murdoch H, Dunlop AJ et al. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci 2010; 13: 327-332.
16. Kim J, Jung SY, Lee YK, Park S, Choi JS, Lee CJ et al. Neuroligin-1 is required for normal expression of LTP and associative fear memory in the amygdala of adult animals. Proc Natl Acad Sci USA 2008; 105: 9087-9092.
17. Ventruti A, Kazdoba TM, Niu S, D'Arcangelo G. Reelin deficiency causes specific defects in the molecular composition of the synapses in the adult brain. Neuroscience 2011; 189: 32-42.
18. Escobar M, Crouzin N, Cavalier M, Quentin J, Roussel J, Lante F et al. Early, timedependent disturbances of hippocampal synaptic transmission and plasticity after in utero immune challenge. Biol Psychiatry 2011; 70: 992-999.
19. Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 2011; 88: 306-316.
20. Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 2010; 42: 1021-1026.
21. Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, Siegel SJ. Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry 2010; 68: 1100-1106.
22. Gandal MJ, Edgar JC, Klook K, Siegel SJ. Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology 2012; 62: 1504-1518.
23. Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 1999; 56: 1001-1005. (Pubitemid 29526383)
24. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-324. (Pubitemid 40469985)
25. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR et al. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 2006; 60: 1231-1240. (Pubitemid 44693537)
26. Virji-Babul N, Cheung T, Weeks D, Herdman AT, Cheyne D. Magnetoencephalographic analysis of cortical activity in adults with and without Down syndrome. J Intellect Disabil Res 2007; 51(Pt 12): 982-987. (Pubitemid 350066607)
27. Politoff AL, Stadter RP, Monson N, Hass P. Cognition-related EEG abnormalities in nondemented Down syndrome subjects. Dementia 1996; 7: 69-75. (Pubitemid 26048418)
28. Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, Aschenbrenner-Scheibe R et al. Gamma oscillations correlate with working memory load in humans. Cereb Cortex 2003; 13: 1369-1374. (Pubitemid 37466784)
29. Engel AK, Singer W. Temporal binding and the neural correlates of sensory awareness. Trends Cogn Sci 2001; 5: 16-25. (Pubitemid 32063335)
30. Gray CM, Konig P, Engel AK, Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature 1989; 338: 334-337. (Pubitemid 19082973)
31. Lee KH, Williams LM, Breakspear M, Gordon E. Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia. Brain res 2003; 41: 57-78. (Pubitemid 36044594)
32. Williams LM, Whitford TJ, Nagy M, Flynn G, Harris AW, Silverstein SM et al. Emotionelicited gamma synchrony in patients with first-episode schizophrenia: a neural correlate of social cognition outcomes. J Psychiatry Neurosci 2009; 34: 303-313.
33. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry 2012; 71: 873-880.
34. Brock J, Brown CC, Boucher J, Rippon G. The temporal binding deficit hypothesis of autism. Dev Psychopathol 2002; 14: 209-224. (Pubitemid 351690094)
35. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009; 459: 698-702.
36. Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci 2008; 1: 6.
37. Sun Y, Farzan F, Barr MS, Kirihara K, Fitzgerald PB, Light GA et al. Gamma oscillations in schizophrenia: mechanisms and clinical significance. Brain Res 2011; 1413: 98-114.
38. Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003; 2: 255-267. (Pubitemid 37345664)
39. Cardin JA, Carlen M, Meletis K, Knoblich U, Zhang F, Deisseroth K et al. Driving fastspiking cells induces gamma rhythm and controls sensory responses. Nature 2009; 459: 663-667.
40. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016-1022. (Pubitemid 44353381)
41. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev 2008; 7: 68-83.
42. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436. (Pubitemid 29402481)
43. Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009; 8: 661-675.
44. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 2009; 158: 705-712.
45. Ehrlichman RS, Luminais SN, White SL, Rudnick ND, Ma N, Dow HC et al. Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Res 2009; 1294: 116-127.
46. Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, Abel T et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res 2004; 29: 1179-1188. (Pubitemid 39023492)
47. Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J et al. Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res 2003; 992: 85-95. (Pubitemid 37356998)
48. Siegel SJ, Connolly P, Liang Y, Lenox RH, Gur RE, Bilker WB et al. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 2003; 28: 675-682.
49. Gandal MJ, Ehrlichman RS, Rudnick ND, Siegel SJ. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008; 157: 95-104.
50. Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. Neurosci Methods 2004; 134: 9-21. (Pubitemid 38224183)
51. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010; 13: 76-83.
52. Deacon RM, Rawlins JN. T-maze alternation in the rodent. Nat Protoc 2006; 1: 7-12.
53. Levitt P, Eagleson KL, Powell EM. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci 2004; 27: 400-406. (Pubitemid 38829255)
54. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 2008; 165: 1585-1593.
55. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002; 12: 1063-1070.
56. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 2001; 11: 543-550. (Pubitemid 33100375)
57. Pagani M, Manouilenko I, Stone-Elander S, Odh R, Salmaso D, Hatherly R et al. Brief report: alterations in cerebral blood flow as assessed by PET/CT in adults with autism spectrum disorder with normal IQ. J Autism Dev Disord 2012; 42: 313-318.
58. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011; 477: 171-178.
59. Dzirasa K, Ramsey AJ, Takahashi DY, Stapleton J, Potes JM, Williams JK et al. Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. J Neurosci 2009; 29: 8215-8224.
60. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 2011; 69: 442-449.
61. Liu SK, Fitzgerald PB, Daigle M, Chen R, Daskalakis ZJ. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol Psychiatry 2009; 65: 503-509.
62. Itil TM, Saletu B, Davis S. EEG findings in chronic schizophrenics based on digital computer period analysis and analog power spectra. Biol Psychiatry 1972; 5: 1-13.
63. Winterer G, Coppola R, Goldberg TE, Egan MF, Jones DW, Sanchez CE et al. Prefrontal broadband noise, working memory, and genetic risk for schizophrenia. Am J Psychiatry 2004; 161: 490-500. (Pubitemid 38326104)
64. Murray AJ, Sauer JF, Riedel G, McClure C, Ansel L, Cheyne L et al. Parvalbumin-positive CA1 interneurons are required for spatial working but not for reference memory. Nat Neurosci 2011; 14: 297-299.
65. Carlen M, Meletis K, Siegle JH, Cardin JA, Futai K, Vierling-Claassen D et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry 2012; 17: 537-548.
66. Korotkova T, Fuchs EC, Ponomarenko A, von Engelhardt J, Monyer H. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron 2010; 68: 557-569.
67. Winterer G, Ziller M, Dorn H, Frick K, Mulert C, Wuebben Y et al. Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin Neurophysiol 2000; 111: 837-849. (Pubitemid 30236430)
68. Frederiksen PK. Letter: Baclofen in the treatment of schizophrenia. Lancet 1975; 1: 702.
69. Davis KL, Hollister LE, Berger PA. Letter: Bacloffen in schizophrenia. Lancet 1976; 1: 1245.
70. Gulmann NC, Bahr B, Andersen B, Eliassen HM. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatr Scand 1976; 54: 287-293.
71. Simpson GM, Branchey MH, Shrivastava RK. Letter: Baclofen in schizophrenia. Lancet 1976; 1: 966-967.
72. Beckmann H, Frische M, Ruther E, Zimmer R. Baclofen (para-chlorphenyl- GABA) in schizophrenia. Pharmakopsychiatr Neuropsychopharmakol 1977; 10: 26-31.
73. Bigelow LB, Nasrallah H, Carman J, Gillin JC, Wyatt RJ. Baclofen treatment in chronic schizophrenia: a clinical trial. Am J Psychiatry 1977; 134: 318-320. (Pubitemid 8059701)
74. Schopf J, Hucker H. Baclofen in the treatment of schizophrenia: a pilot study. Pharmakopsychiatr Neuropsychopharmakol 1977; 10: 89-91. (Pubitemid 8091697)
75. Simpson GM, Lee JH, Shrivastava RK, Branchey MH. Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacol Bull 1978; 14: 16-18. (Pubitemid 8313257)
76. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007; 318: 1645-1647. (Pubitemid 350233667)
77. Castner SA, Arriza JL, Roberts JC, Mrzljak L, Christian EP, Williams GV. Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023. Biol Psychiatry 2010; 67: 998-1001.
78. Ma J, Leung LS. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology (Berl) 2007; 191: 961-974. (Pubitemid 46399137)
79. Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P et al. Effects of gammaaminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007; 64: 156-167. (Pubitemid 46220773)
80. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC et al. Cognitive improvement after treatment with second-generation antipsychotic medications in firstepisode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115-1122. (Pubitemid 47529336)
81. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 2006; 63: 1189-1197. (Pubitemid 44708076)